Effectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: analyses from the EASYDia trial

Leiter L. A., Shestakova M. V., Satman I.

DIABETOLOGY & METABOLIC SYNDROME, vol.10, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 10
  • Publication Date: 2018
  • Doi Number: 10.1186/s13098-018-0331-8
  • Journal Name: DIABETOLOGY & METABOLIC SYNDROME
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Keywords: Type 2 diabetes, Gliclazide, Glycemic control, Tolerability, Real-world, CARDIOVASCULAR OUTCOMES, RAMADAN, HYPOGLYCEMIA, EMPAGLIFLOZIN, SULFONYLUREA, SAXAGLIPTIN, SITAGLIPTIN, MORTALITY
  • Istanbul University Affiliated: Yes

Abstract

Background: Although the number of antihyperglycemic agents has expanded significantly, sulfonylureas (in particular gliclazide) remain an important option because of a variety of patient and health system factors. The large, real world, observational, and international EASYDia trial evaluated the effectiveness of gliclazide modified release (MR) 60 mg in individuals with type 2 diabetes with a broad range of diabetes history, body mass index (BMI) and background antihyperglycemic treatment.